150 related articles for article (PubMed ID: 9679765)
1. Down-regulation of BRCA1 and BRCA2 in human ovarian cancer cells exposed to adriamycin and ultraviolet radiation.
Fan S; Twu NF; Wang JA; Yuan RQ; Andres J; Goldberg ID; Rosen EM
Int J Cancer; 1998 Aug; 77(4):600-9. PubMed ID: 9679765
[TBL] [Abstract][Full Text] [Related]
2. Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents.
Andres JL; Fan S; Turkel GJ; Wang JA; Twu NF; Yuan RQ; Lamszus K; Goldberg ID; Rosen EM
Oncogene; 1998 Apr; 16(17):2229-41. PubMed ID: 9619832
[TBL] [Abstract][Full Text] [Related]
3. Regulation of BRCA1 and BRCA2 transcript in response to cisplatin, adriamycin, taxol and ionising radiation is correlated to p53 functional status in ovarian cancer cell lines.
Aunoble B; Bernard-Gallon D; Bignon YJ
Oncol Rep; 2001; 8(3):663-8. PubMed ID: 11295099
[TBL] [Abstract][Full Text] [Related]
4. Coordinate alterations in the expression of BRCA1, BRCA2, p300, and Rad51 in response to genotoxic and other stresses in human prostate cancer cells.
Yuan R; Fan S; Wang JA; Meng Q; Ma Y; Schreiber D; Goldberg ID; Rosen EM
Prostate; 1999 Jun; 40(1):37-49. PubMed ID: 10344722
[TBL] [Abstract][Full Text] [Related]
5. Ultraviolet irradiation induces BRCA2 protein depletion through a p53-independent and protein synthesis-dependent pathway.
Wang SC; Makino K; Su LK; Pao AY; Kim JS; Hung MC
Cancer Res; 2001 Apr; 61(7):2838-42. PubMed ID: 11306454
[TBL] [Abstract][Full Text] [Related]
6. Ultraviolet radiation down-regulates expression of the cell-cycle inhibitor p21WAF1/CIP1 in human cancer cells independently of p53.
Wang JA; Fan S; Yuan RQ; Ma YX; Meng Q; Goldberg ID; Rosen EM
Int J Radiat Biol; 1999 Mar; 75(3):301-16. PubMed ID: 10203181
[TBL] [Abstract][Full Text] [Related]
7. Changes in BRCA1 and BRCA2 expression produced by chemotherapeutic agents in human breast cancer cells.
Su J; Ciftci K
Int J Biochem Cell Biol; 2002 Aug; 34(8):950-7. PubMed ID: 12007633
[TBL] [Abstract][Full Text] [Related]
8. Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines.
Rauh-Adelmann C; Lau KM; Sabeti N; Long JP; Mok SC; Ho SM
Mol Carcinog; 2000 Aug; 28(4):236-46. PubMed ID: 10972993
[TBL] [Abstract][Full Text] [Related]
9. P53-independent downregulation of p73 in human cancer cells treated with Adriamycin.
Yuan R; Meng Q; Hu H; Goldberg ID; Rosen EM; Fan S
Cancer Chemother Pharmacol; 2001; 47(2):161-9. PubMed ID: 11269743
[TBL] [Abstract][Full Text] [Related]
10. P53-independent down-regulation of Mdm2 in human cancer cells treated with adriamycin.
Ma Y; Yuan R; Meng Q; Goldberg ID; Rosen EM; Fan S
Mol Cell Biol Res Commun; 2000 Feb; 3(2):122-8. PubMed ID: 10775510
[TBL] [Abstract][Full Text] [Related]
11. Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations.
Zweemer RP; Shaw PA; Verheijen RM; Ryan A; Berchuck A; Ponder BA; Risch H; McLaughlin JR; Narod SA; Menko FH; Kenemans P; Jacobs IJ
J Clin Pathol; 1999 May; 52(5):372-5. PubMed ID: 10560359
[TBL] [Abstract][Full Text] [Related]
12. The Fanconi anemia/BRCA pathway is involved in DNA interstrand cross-link repair of adriamycin-resistant leukemia cells.
Yao C; Du W; Chen H; Xiao S; Huang L; Chen F
Leuk Lymphoma; 2015 Mar; 56(3):755-62. PubMed ID: 24996439
[TBL] [Abstract][Full Text] [Related]
13. Messenger RNA expression of resistance proteins and related factors in human ovarian carcinoma cell lines resistant to doxorubicin, taxol and cisplatin.
Masanek U; Stammler G; Volm M
Anticancer Drugs; 1997 Feb; 8(2):189-98. PubMed ID: 9073315
[TBL] [Abstract][Full Text] [Related]
14. Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line.
Son YS; Suh JM; Ahn SH; Kim JC; Yi JY; Hur KC; Hong WS; Muller MT; Chung IK
Cancer Chemother Pharmacol; 1998; 41(5):353-60. PubMed ID: 9523730
[TBL] [Abstract][Full Text] [Related]
15. Nonhomologous end-joining of ionizing radiation-induced DNA double-stranded breaks in human tumor cells deficient in BRCA1 or BRCA2.
Wang H; Zeng ZC; Bui TA; DiBiase SJ; Qin W; Xia F; Powell SN; Iliakis G
Cancer Res; 2001 Jan; 61(1):270-7. PubMed ID: 11196174
[TBL] [Abstract][Full Text] [Related]
16. p53 mediates repression of the BRCA2 promoter and down-regulation of BRCA2 mRNA and protein levels in response to DNA damage.
Wu K; Jiang SW; Couch FJ
J Biol Chem; 2003 May; 278(18):15652-60. PubMed ID: 12591928
[TBL] [Abstract][Full Text] [Related]
17. Expression and mutations of BRCA in breast cancer and ovarian cancer: Evidence from bioinformatics analyses.
Wang Z; Zhang J; Zhang Y; Deng Q; Liang H
Int J Mol Med; 2018 Dec; 42(6):3542-3550. PubMed ID: 30221688
[TBL] [Abstract][Full Text] [Related]
18. BRCA1 as a potential human prostate tumor suppressor: modulation of proliferation, damage responses and expression of cell regulatory proteins.
Fan S; Wang JA; Yuan RQ; Ma YX; Meng Q; Erdos MR; Brody LC; Goldberg ID; Rosen EM
Oncogene; 1998 Jun; 16(23):3069-82. PubMed ID: 9662340
[TBL] [Abstract][Full Text] [Related]
19. p53-dependent radioresistance in ovarian carcinoma cell lines.
Concin N; Zeillinger C; Stimpfel M; Schiebel I; Tong D; Wolff U; Reiner A; Leodolter S; Zeillinger R
Cancer Lett; 2000 Mar; 150(2):191-9. PubMed ID: 10704742
[TBL] [Abstract][Full Text] [Related]
20. A critical dose of doxorubicin is required to alter the gene expression profiles in MCF-7 cells acquiring multidrug resistance.
Tsou SH; Chen TM; Hsiao HT; Chen YH
PLoS One; 2015; 10(1):e0116747. PubMed ID: 25635866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
